⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14889774 | 0.83 | CYP2C19 (0.30) | — | |
| SCHEMBL17152527 | 0.78 | CYP2C19 (0.38) | — | |
| SCHEMBL23539431 | 0.75 | ALDH1A1 (0.31) | — | |
| SCHEMBL14152933 | 0.74 | — | — | |
| SCHEMBL14889644 | 0.73 | — | — | |
| SCHEMBL15059607 | 0.72 | CYP2C19 (0.35) | — | |
| SCHEMBL2582156 | 0.71 | — | — | |
| SCHEMBL630218 | 0.71 | CYP2C19 (0.39) | — | |
| SCHEMBL7038806 | 0.71 | CYP2C19 (0.34) | — | |
| SCHEMBL1515582 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901157-B2 | Compositions and methods of use of ritonavir for treating HCV | ABBVIE INC. (US) | 2014-12-02 | — | — | US | claimed |
| CN-101495095-B | Method for precipitation and isolation of 6, 6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical preparations containing the same | MERCK SHARP & DOHME | 2013-05-29 | — | — | CN | claimed |
| US-20120294935-A1 | PROCESS FOR THE PRECIPITATION AND ISOLATION OF 6,6-DIMETHYL-3-AZA-BICYCLO [3.1.0] HEXANE-AMIDE COMPOUNDS BY CONTROLLED PRECIPITATION AND PHARMACEUTICAL FORMULATIONS CONTAINING SAME | ZARKADAS DIMITRIOS (US) | 2012-11-22 | — | — | US | claimed |
| US-20110091423-A1 | COMPOSITIONS AND METHODS OF USE OF RITONAVIR FOR TREATING HCV | ABBOTT LABORATORIES (US) | 2011-04-21 | — | — | US | claimed |
| CN-101495095-A | Method for precipitation and isolation of 6, 6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical preparations containing the same | SCHERING CORP (US) | 2009-07-29 | — | — | CN | claimed |
| EP-2012753-A2 | PROCESS FOR THE PRECIPITATION AND ISOLATION OF 6,6-DIMETHYL-3-AZA-BICYCLO [3.1.0]HEXANE-AMIDE COMPOUNDS BY CONTROLLED PRECIPITATION AND PHARMACEUTICAL FORMULATIONS CONTAINING SAME | SCHERING CORPORATION (US) | 2009-01-14 | — | — | EP | claimed |
| EP-2007381-A2 | COMPOSITIONS AND METHODS OF USE OF RITONAVIR FOR TREATING HCV | Abbott Laboratories (US) | 2008-12-31 | — | — | EP | claimed |
| US-20080254128-A1 | Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same | MERCK SHARP & DOHME CORP. | 2008-10-16 | — | — | US | claimed |
| US-20080193518-A1 | Process for the precipitation and isolation of 6,6-Dimethyl-3-Aza Bicyclo [3.1.0] Hexane-Amide compounds by controlled precipitation and pharmaceutical formulations containing same | SCHERING CORPORATION | 2008-08-14 | — | — | US | claimed |
| WO-2007127380-A2 | PROCESS FOR THE PRECIPITATION AND ISOLATION OF 6,6-DIMETHYL-3-AZA-BICYCLO [3.1.0] HEXANE-AMIDE COMPOUNDS BY CONTROLLED PRECIPITATION AND PHARMACEUTICAL FORMULATIONS CONTAINING SAME | SCHERING CORPORATION (US) | 2007-11-08 | — | — | WO | claimed |
| WO-2007103934-A2 | COMPOSITIONS AND METHODS OF USE OF RITONAVIR FOR TREATING HCV | ABBOTT LABORATORIES (US) | 2007-09-13 | — | — | WO | claimed |
| US-20070207122-A1 | COMPOSITONS AND METHODS OF USE OF RITONAVIR FOR TREATING HCV | ABBOTT LABORATORIES | 2007-09-06 | — | — | US | claimed |
| EP-2477980-B1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO LTD (TW) | 2016-06-08 | — | — | EP | disclosed |
| EP-2274281-B1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO LTD (TW) | 2015-05-27 | — | — | EP | disclosed |
| US-8901157-B2 | Compositions and methods of use of ritonavir for treating HCV | ABBVIE INC. (US) | 2014-12-02 | — | — | US | disclosed |
| CN-101495095-B | Method for precipitation and isolation of 6, 6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical preparations containing the same | MERCK SHARP & DOHME | 2013-05-29 | — | — | CN | disclosed |
| WO-2007127380-A2 | PROCESS FOR THE PRECIPITATION AND ISOLATION OF 6,6-DIMETHYL-3-AZA-BICYCLO [3.1.0] HEXANE-AMIDE COMPOUNDS BY CONTROLLED PRECIPITATION AND PHARMACEUTICAL FORMULATIONS CONTAINING SAME | SCHERING CORPORATION (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007121124-A2 | HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007103934-A2 | COMPOSITIONS AND METHODS OF USE OF RITONAVIR FOR TREATING HCV | ABBOTT LABORATORIES (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070207122-A1 | COMPOSITONS AND METHODS OF USE OF RITONAVIR FOR TREATING HCV | ABBOTT LABORATORIES | 2007-09-06 | — | — | US | disclosed |